Extended therapy with Lu-177-PSMA-617 in patients with high tumor load metastatic castration-resistant prostate cancer

Conclusions: Long progression free survival times and the absence of serious adverse events in this patient group encourage further evaluation of extended radioligand therapy in patients with advanced disease. Figure: 68Ga-PSMA PET/CT images of a patient undergoing extended therapy with 10 cycles during 30 months until progression.

Source: Journal of Nuclear Medicine - May 14, 2020 Category: Nuclear Medicine Authors: Mader, N., Baumgarten, J., Groner, D., Nguyen Ngoc, C., Davis, K., Banek, S., Tselis, N., Happel, C., Gruenwald, F., Sabet, A. Tags: GU - Radioligand Therapy (Poster Session) Source Type: research